Posted by Michael Wonder on 03 Apr 2025
GSK Korea's long-acting HIV injection therapy gains insurance benefit
1 April 2025 - GSK Korea said its long-acting injectable HIV-1 combination treatment, Vocabria (cabotegravir 600 mg) and Rekambys (rilpivirine 900 mg), began to be covered by Korea’s national health insurance system today.
The therapy received regulatory approval from the Ministry of Food and Drug Safety in February 2022 for virologically suppressed adults with no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine. The reimbursement criteria align with these indications.
